Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy

Abstract: In myelofibrosis (MF), driver mutations in JAK2, MPL, or CALR impact survival and progression to blast phase, with the greatest risk conferred by triple-negative status. Subclonal mutations, including mutations in high–molecular risk (HMR) genes, such as ASXL1, EZH2, IDH1/2, and SRSF2 have...

وصف كامل

التفاصيل البيبلوغرافية

الحاوية / القاعدة:	Blood Advances
المؤلفون الرئيسيون:	Jay Y. Spiegel, Caroline McNamara, James A. Kennedy, Tony Panzarella, Andrea Arruda, Tracy Stockley, Mahadeo Sukhai, Mariam Thomas, Justyna Bartoszko, Jenny Ho, Nancy Siddiq, Dawn Maze, Aaron Schimmer, Andre Schuh, Hassan Sibai, Karen Yee, Jamie Claudio, Rebecca Devlin, Mark D. Minden, Suzanne Kamel-Reid, Vikas Gupta
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	Elsevier 2017-09-01
الوصول للمادة أونلاين:	http://www.sciencedirect.com/science/article/pii/S2473952920303141